These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 18566539

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW, Druker BJ.
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [Abstract] [Full Text] [Related]

  • 3. CML: a model for targeted therapy.
    Cilloni D, Saglio G.
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):285-94. PubMed ID: 19959080
    [Abstract] [Full Text] [Related]

  • 4. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J.
    Lab Hematol; 2004 Sep; 10(3):181-4. PubMed ID: 15529444
    [No Abstract] [Full Text] [Related]

  • 5. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G, Iacobucci I, Soverini S, Cilloni D, Saglio G, Pane F, Baccarani M.
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [Abstract] [Full Text] [Related]

  • 6. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 7. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb 15; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 8. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A.
    Semin Hematol; 2003 Apr 15; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [Abstract] [Full Text] [Related]

  • 9. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.
    Haematologica; 2008 Feb 15; 93(2):186-92. PubMed ID: 18223278
    [Abstract] [Full Text] [Related]

  • 10. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
    Haematologica; 2005 Apr 15; 90(4):534-41. PubMed ID: 15820950
    [Abstract] [Full Text] [Related]

  • 11. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X, Tiwari AK, Sun Y, Ding PR, Ashby CR, Chen ZS.
    Leuk Res; 2010 Oct 15; 34(10):1255-68. PubMed ID: 20537386
    [Abstract] [Full Text] [Related]

  • 12. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.
    Leukemia; 2002 Nov 15; 16(11):2190-6. PubMed ID: 12399961
    [Abstract] [Full Text] [Related]

  • 13. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH, Tang JL, Chen RL, Li CC, Lee CP.
    Leuk Res; 2008 Nov 15; 32(11):1724-34. PubMed ID: 18603297
    [Abstract] [Full Text] [Related]

  • 14. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.
    J Clin Oncol; 2010 Apr 10; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract] [Full Text] [Related]

  • 15. Imatinib resistance in CML.
    Volpe G, Panuzzo C, Ulisciani S, Cilloni D.
    Cancer Lett; 2009 Feb 08; 274(1):1-9. PubMed ID: 18653275
    [Abstract] [Full Text] [Related]

  • 16. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H.
    Acta Haematol; 2012 Feb 08; 127(1):34-42. PubMed ID: 22005133
    [Abstract] [Full Text] [Related]

  • 17. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 08; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 18. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N.
    Rinsho Byori; 2004 Feb 08; 52(2):136-44. PubMed ID: 15027317
    [Abstract] [Full Text] [Related]

  • 19. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R, Kimura S.
    Expert Rev Anticancer Ther; 2008 Sep 08; 8(9):1387-98. PubMed ID: 18759691
    [Abstract] [Full Text] [Related]

  • 20. Glivec and CML: a lucky date.
    Saglio G, Cilloni D, Rancati F, Boano L.
    J Biol Regul Homeost Agents; 2004 Sep 08; 18(2):246-51. PubMed ID: 15739279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.